舒洛地特治疗糖尿病肾病的临床观察被引量：2

导出

摘要目的观察舒洛地特对糖尿病肾病(DN)的疗效。方法将76例DN-Ⅳ期患者随机分为两组:舒洛地特与合厄贝沙坦联合组38例,单用厄贝沙坦组38例,随访12周。比较治疗前后24 h尿蛋白定量、BUN、血肌酐、血清光抑素C(Cys-C)的变化。结果治疗后两组24h尿蛋白均较治疗前有显著下降(P<0.05),联合组与厄贝沙坦组比较差异有统计学意义(P<0.05)。结论舒洛地特联合厄贝沙坦能有效降低DN患者的尿蛋白,效果优于单用厄贝沙坦。

作者杨慧慧鲁平阚全娥

机构地区河南省人民医院内分泌科

出处《医药论坛杂志》 2015年第11期152-153,共2页 Journal of Medical Forum

关键词糖尿病肾病舒洛地特厄贝沙坦

分类号 R587.2 [医药卫生—内分泌]

引文网络
相关文献

参考文献8

1K eane WF,Brenner BM, de Zeeuw D, et al. The risk of develo- ping end - stage renal disease in patients with type 2 diabetes and nephropathy : theRENAAL study [J]. Kidney Int, 2003,63 : 1499-507.
2Lewis E J, Hunsicker LG, Clarke WR, et al. Renoprotective dffect of the angioten - sin - receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes [ J]. N Engl J Med, 2001,345:851-850.
3Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardivaeular outcomes in patients with type 2 diabetes and nephropathy[ J]. N Engl J Med,2001,345 :861-9.
4Gambaro G, Ceol M, Antonello A. The Steno hypothesis for cardi- ovascular and renal disease revisited. In : Mogensen CE, editor. The kidney and hypertension in diabetes mellitus. 6th ed[ M]. Boston ( MA ) : Kluwer Academic Publishers, 2003 : 27-43.
5Lewis E J, Lewis JB, 1-Iunsicker LG. Interim analysis of a pilot tri- al of sulodexide in type 2 diabetic nephropathy with microalbu- minuria[ abstract]. J Am Soc Nephro1,2005,16:58A.
6唐琳,陈慧娟,房豫东,李慧,张娜娜,王刘伟,杨自君.舒洛地特对原发性膜性肾病的疗效观察[J].中国实用医刊,2013,40(11):16-18. 被引量：5
7Gambaro G, Venturini AP, Noonan DM, et al. Treatment with a glyeosaminoglycan formulation ameliorates experimental diabetic nephropathy [ J ]. Kidney Int, 1994,46:797-806.
8Ceol M, Gamharo G, Nedieh A, et al. Glycosaminogiycan therapy prevents TGF- 131 over- expression and pathological changes in renal tissue of long - term diabetic rats [ J ]. J Am Soc Nephrol, 2001,12:2080-7.

二级参考文献11

1Glassock RJ. Diagnosis and natural course of membranous nephrop-athy [ J]. Semin Nephml,2003 ,23(4) :324-332.
2Cattam DC. Idiopathic membranous glomerulonephritis [ J]. KidneyInt,2001,59(5) : 1983-1994.
3Blouza S, Dakhli S,Abid H,et al. Efficacy of low-dose oral sulodex-ide in the management of diabetic nephropathy [ J]. J Nephrol,2010,23(4) :415-424.
4Williams ME,Tuttle KR. The next generation of diabetic nephropathytherapies : An update [ J ]. Adv Chronic Kidney Dis, 2005 , 12 ( 2 ):212-222.
5Lambers HJ,Fowler MJ,Volgi J,et al. Rationale for and study designof the sulodexide trials in type 2 diabetic,hypertensive patients withmicroalbuminuria or overt nephropathy[ J]. Diabetic Med, 2007 , 24.11) :1290-1295.
6Weigert C, Brodbeck K, Haring HU, et al. Low-molecular-weightheparin prevents high glucose and phorbol ester-induced TGF-beta 1gene activation [J], Kidney Int,2001, 60(3) -.935-943.
7Ceol M,Gambaro G, Sauer U, et al. Glycosaminoglycan therapy pre-vents TGF-bet al overexpression and pathologic changes in renal tissueof long-term diabetic rats [ J]. J Am Soc Nephrol,2000,11 (12):2324-2336.
8Gambaro G,Kinalska I,Oksa A, et al. Oral sulodexide reduces al-buminuria in microalbuminuric and macroalbuminuric type 1 and type2diabetic patients: the Di. N. A. S. randomized trial [ J]. J Am SocNephrol,2002,13(6) :1615-1625.
9陈铖,梁伟,丁国华,易家志.舒洛地特对老龄糖尿病大鼠足细胞的保护作用[J].医药导报,2010,29(10):1258-1261. 被引量：4
10任健,苏颉,黄灿,田晨光.舒洛地特治疗2型糖尿病肾病尿微量白蛋白的疗效观察[J].中国现代医药杂志,2010,12(11):31-33. 被引量：3